Drug Trial Radar · NCT04289285
Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia
Last checked: Nov 19, 2026Latest source record: Apr 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
804
Actual
Start
Apr 29, 2020
Primary completion
Feb 9, 2022
Study completion Feb 9, 2022
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol(LDL-C) uptake. This study is being done to investigate the effects of IBI306 in Chinese people with non-familial hypercholesterolemia with very high or high cardiovascular risk. This study will see if IBI306 will reduce low density lipoprotein cholesterol (LDL-C) in Chinese people who are taking a certain type of lipid-lowering medication (statins with or without ezetimibe) and whether it causes any side effects
Conditions
- Hypercholesterolemia
Interventions
IBI306 450mg SC Q4WDrug
Subjects will receive IBI306 450mg every 4 weeks subcutaneously.
Placebo SC Q4WDrug
Subjects will receive placebo every 4 weeks subcutaneously.
IBI306 600mg SC Q6WDrug
Subjects will receive IBI306 600mg every 6 weeks subcutaneously.
Placebo SC Q6WOther
Subjects will receive placebo every 6 weeks subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at week 48Time frame: Week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.